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ProteomicsDespite its ubiquity in cancer, linkwith other pathologies, and role in promoting adaptive evolution, the effects of
aneuploidy or imbalanced chromosomal content on cellular physiology have remained incompletely character-
ized. Signiﬁcantly, it appears that the detrimental aswell as beneﬁcial effects of aneuploidy are due to the altered
gene expression elicited by the aneuploid state. In this reviewwe examine the correlation between chromosome
copy number changes and gene expression in aneuploid cells. We discuss the primary effects of aneuploidy on
gene expression and describe the cellular response to altered mRNA and protein levels. Moreover, we consider
compensatory mechanisms that may ameliorate imbalanced gene expression and restore protein homeostasis
in aneuploid cells. Finally, we propose a novel hypothesis to explain the hitherto enigmatic abundance compen-
sation of proteins encoded on supernumerary chromosomes.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Most eukaryotic species are diploid, meaning that each of the chro-
mosomes is present in the nucleus in a pair of homologs. This balanced
state is called euploidy (from Greek: “eu” = good; “ploos” = fold).
Haploid cells, containing one copy of each chromosome, or polyploids,
with multiple sets, maintain the balance between chromosomes, de-
spite changes in total chromosome numbers. In contrast, aneuploidy
describes the state where the chromosome number does not corre-
spond to amultiple of a haploid chromosome set; i.e. one ormore chro-
mosomes are present in unequal numbers. Aneuploidy mostly arises as
a consequence of chromosome missegregation due to defects such as
spindle multipolarity, failure of sister chromatid cohesion or an impaired
spindle assembly checkpoint (Fig. 1). As chromosome missegregation
leads to gains and losses of whole chromosomes, this type of abnormal
chromosome number is often called “whole chromosomal” aneuploidy
[1].Whole chromosomal aneuploidy is one of the leading causes of spon-
taneous abortions and the rare survivors are born with severe handicaps,
such as in case of trisomy 13, 18 or 21 (Patau, Edwards and Down syn-
drome, respectively). In contrast, copy number changes that affect only
parts of chromosomes are described as “segmental” or “structural” aneu-
ploidy. This can arise due to DNA replication and repair errors that result
in deletion, ampliﬁcation or rearrangements of chromosomal regions
(reviewed in [2]). Recent advances inwhole-genome sequencinghave re-
vealed a frequent occurrence of segmental aneuploidy in human cells, intability, Max Planck Institute of
many. Tel.: +49 89 8578 3145;
vá).
ights reserved.particular in leukemias and lymphomas, and its association with neuro-
logical defects and other pathologies [3].
Although whole chromosomal aneuploidy (hereafter aneuploidy)
can occur by a sporadic error, it often appears as a consequence of an on-
going defect in faithful transmission of chromosomes, so called chromo-
somal instability — CIN (for a recent review see [4]). Hence, cells with
variable aneuploidy arise within a population. It should be noted that
not all aneuploid cells display CIN and that aneuploidy-induced CIN
varies greatly in degree among different aneuploid karyotypes [5,6].
On the other hand, CIN, and, consequently, aneuploidy are found in
the majority of solid tumors. In fact, there is strong evidence that aneu-
ploidy contributes to tumor formation (reviewed in [7–9]) and it is as-
sociated with high malignancy, poor prognosis and drug resistance, at
least in some cancer types [10,11]. Despite the frequent occurrence of
aneuploidy and its links to pathologies in humans, the mechanisms un-
derlying the effects of aneuploidy on cellular physiology are only poorly
understood. Only recently have new discoveries shed ﬁrst light on the
effects that aneuploidy elicits in eukaryotic cells.
2. Consequences of aneuploidy
Aneuploidy has been difﬁcult to study. Most cancer cell lines are an-
euploid, but they also contain multiple additional mutations, making it
hard to separate the physiological consequences of aneuploidy from
other effects. Recent breakthroughs in understanding aneuploidy have
been fueled by experimental approaches exploiting model aneuploid
cells that are derived from euploid cells and thus can be directly com-
pared with their cognate diploid counterparts (for example [12–18],
Fig. 2). Comparison of multiple different aneuploids has revealed that
the phenotypes of aneuploid cells differ widely, both qualitatively and
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Fig. 1. Causes and consequences of aneuploidy. Aneuploidy arises as a result of circumstances that lead to chromosomemissegregation, such as spindle multipolarity, compromised sister
chromatid cohesion, or impaired function of the Spindle Assembly Checkpoint (SAC). An example of chromosome gain is depicted, as this situation is well studied. The consequences of
aneuploidy arewell conserved from yeast toman and appear to be largely independent of the identity of the extra chromosome(s). They include proteotoxic stress, impaired proliferation,
and chromosomal instability. Aneuploidy can also allow for the development of new traits, thus facilitating adaptation to hostile environments as has been shown in budding yeast.
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hibits a unique set of phenotypes. However, several striking similarities
are conserved among different aneuploidies and species suggesting that
aberrant chromosome numbers often alter cellular physiology in amark-
edly uniform way, leading to slow proliferation, global gene expression
changes as well as sensitivity to multiple drugs (Fig. 1). Importantly, at
least in the case of aneuploid cells harboring extranumerary chromo-
somes, the detrimental consequences are due to the expression of the
genes encoded on the aneuploid chromosomes. This was demonstrated
in an elegant experiment using disomic budding yeast cells: cells contain-
ing an extra yeast chromosomeproliferated slowly and showed increased
sensitivity to inhibitors of protein synthesis, whereas cells modiﬁed by
the presence of an artiﬁcial chromosome lacking sequences suitable for
the yeast transcription machinery were unaffected [14]. The proliferative
disadvantage elicited by supernumerary chromosomes can in principal
arise as a consequence of over-expression of one particular gene located
on the extra chromosome(s). For example, in budding yeast it has been
shown that disomy of chromosomeVI is not compatiblewith survival be-
cause it contains the TUB2 gene which encodes tubulin β; even one extra
copy of TUB2 is lethal in budding yeast [19]. However, most of the evi-
dence suggests that this is rather an exception. A systematic genome-
wide study of segmental aneuploidy demonstrated that only 50 out of
the approximately 15000 genes in Drosophila are haploinsufﬁcient,
while one is triplo-lethal [20]. Larger deletions and duplications result
in reduced viability and fertility that depends on the extent of aneuploidy,
and not on any particular region or gene [20]. Thus, while active tran-
scription of the extra genes and presumably the synthesis, folding and
degradation of the resulting proteins is required for the expression of
the aneuploid phenotype in cells carrying extra chromosomes, the actual
identity and function of the extra genes themselves is not the critical fac-
tor. Thismight explainwhy the consequences of extra chromosomenum-
bers are remarkably similar regardless of the identity of the extra
chromosomes and encoded genes. The recurrent motifs in the observed
phenotypes of such aneuploids are impaired proliferation, extended G1
and S phases, changes in metabolism, sensitivity to speciﬁc drugs and a
recurrent pattern of transcriptional changes [18,21]. However, the precise
triggers of the cellular response to aneuploidy remain enigmatic.
Notably, aneuploidy does occur spontaneously in nature, indicating
that it is selectively neutral or evenbeneﬁcial under certain circumstances
(Fig. 1). For instance, several lager-brewing yeast strains are characterized
by segmental aneuploidy [22], while Saccharomyces cerevisiae isolates
from oak and from sakewere shown to exhibit whole chromosomal an-
euploidy [23]. Naturally occurring copy number variations and wholechromosomal aneuploidy have been well documented in parasitic spe-
cies of genus Leishmania, Giardia and Trypanosoma aswell as in the path-
ogenic fungus Batrachochytrium dendrobatidis [24–27]. Further, healthy
human brain [28] and liver [29] both contain appreciable levels of aneu-
ploid cells, indicating that aneuploidy constitutes a normal feature of
these organs and is important for their proper function. Intriguingly, em-
bryonic stem cells have been repeatedly demonstrated to adapt to in vitro
culturing by accruing whole chromosomal abnormalities (reviewed in
[30]), a property that may promote their tumorigenicity [31]. Finally,
most established cancers and cancer cell lines exhibit complex aneuploi-
dy that is not associated with slower proliferation, but in contrast posi-
tively correlates with tumor malignancy and drug resistance [32].
The beneﬁcial effects of aneuploidy seem to depend, to a large
extent, on context and aneuploidy appears to play a prominent role in
cellular adaptation to hostile environmental conditions. Thus, aneuploi-
dy confers antifungal resistance on the pathogenic yeasts Candida
albicans [23] and Cryptococcus neoformans [33], and in budding yeast,
complex aneuploidy facilitates adaptation to a plethora of inhibitory
conditions [14]. Further, aneuploid hepatocytes were demonstrated to
be highly enriched in mice resistant to chronic liver injury [34]. In sev-
eral of the instances cited [35,33,16], the increased ﬁtness could be di-
rectly linked with the enhanced expression of genes encoded on
supernumerary chromosomes. A recent intriguing study has shed fur-
ther light on the role of aneuploidy in facilitating adaptation to harsh en-
vironments by showing that aneuploidy often represents a crude “quick
ﬁx” that promotes survival in response to acute stress, but that subse-
quently more efﬁcient solutions take over [36]. Certainly, however,
more studies are needed to fully unravel how aneuploidy exerts its ben-
eﬁcial effects and how this is linked with the higher degree of CIN and
consequently, genetic variability, exhibited by aneuploid cells.
As emphasized above, the striking phenotypes of aneuploid cells
arise due to altered gene expression. The primary, cis expression chang-
es affect the abundance of gene products encoded on the aneuploid chro-
mosome. Secondary, trans expression changes arise genome-wide, either
as a physiological response to aneuploidy, or as a consequence of the al-
tered expression of transcriptional regulators encoded on the aneuploid
chromosomes (as shown in [37]). Altered gene expression leads to per-
turbations of stoichiometric relationships of regulatory gene products
or subunits of macromolecular complexes, which according to the pre-
viously proposed dosage balance hypothesis contributes to the detri-
mental phenotypes of aneuploidy (reviewed in [38]). In this review
we examine how gene expression scales with the chromosome copy
number changes in aneuploid cells. We discuss the primary effects of
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Fig. 2.Model systems used for studies on aneuploidy. A. Chromosome transfer into budding yeast cells is usually performed by themating ofwild type haploid yeast cells (recipient)with a
donor that carries a mutation that impairs the fusion of nuclei and contains a marked chromosome (donor). During mating the two nuclei fail to fuse, but instead a random transfer of
chromosomes from the donor nucleus to the recipient nucleus can occur. Recipient cells that contain the desired chromosome gain the ability to grow on selective medium. B. Meiosis
of triploid (or pentaploid) yeast cells results in uneven chromosome segregation due to a failure to form homologue pairs in meiosis. Many of the spores are not viable; the survivors
have variable complex karyotypes. C. Targeted chromosome removal is in yeast usually mediated by activation of a strong promoter, such as Gal1-10, integrated into the vicinity of a cen-
tromere. Strong transcription over centromeric regions interferes with faithful chromosome segregation and leads to frequent loss of the targeted chromosome. D. During microcell-
mediated chromosome transfer, individual membrane vesicles containing chromosomes are isolated from donor cells treated with colcemid and fused to the recipient cells. Transferred
chromosomes can contain a marker gene, which allows selection for cells that gained the requested chromosome. E. Targeted chromosome removal is enabled by selection against an
individual marked chromosome. So far this technique has been shown to correct trisomy 21, suggesting that it could be used to generate monosomy. F. Chromosome missegregation
due tomultipolar mitosis (e.g. after erroneous tetraploidization) or (G) by other errors duringmitotic division (e.g. after inhibition of microtubule polymerization) leads to the formation
of cells with variable aneuploid karyotypes. Chromosomemissegregation often leads to a p53-dependent death of the daughter cells; the triggers of the p53-dependent response are not
yet understood.
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with the altered mRNA and protein levels. Moreover, we consider
mechanisms by which aneuploid cells may alleviate the effects of al-
tered gene expression to restore protein homeostasis.
3. Targeting the culprit by leveling the DNA copy number
Gain of a missing chromosome or loss of the extra one should allevi-
ate all of the defects linked to aneuploidy. In the latter context, this hasbeen recently achieved in induced pluripotent stem cells (iPSCs) from
Down syndrome ﬁbroblasts by introducing a TKNEO (thymidine kinase
with neomycin phosphotransferase reporter gene) transgene into one
copy of chromosome 21 [39]. The presence of TKNEO renders cells sen-
sitive to thymidine analogs, which allows selection of cells that lost the
marked chromosome 21. The chromosome loss restored diploidy and
provided a growth advantage over the original trisomy. In another re-
cent study, heterochromatinization of a supernumerary chromosome
21 using a modiﬁed X-chromosome silencing system led to decreased
476 N. Donnelly, Z. Storchová / Biochimica et Biophysica Acta 1843 (2014) 473–481gene expression and markedly improved proliferation of the cells [40].
These studies demonstrate that cells that become euploid by loss of
extra chromosome(s) proliferate more efﬁciently and thus outgrow
the population [39,40].
There is some evidence suggesting that “euploidization” to normal
chromosome numbers can also occur spontaneously; however, this
does not seem to be a default fate. Monosomic budding yeasts gain the
missing chromosome within 20–30 generations, although the rates vary
for different chromosomes [41,42]. The mechanism of the reduplication
of the missing chromosome is poorly understood. In plants monosomy
appears to be relatively stable [43]. Similarly, in Drosophila strains carry-
ing variable deletions, no evidence of selective ampliﬁcation that restored
normal genedosagewas found [44]. Only scant data on euploidization are
available for aneuploids with extra chromosomes. A series of aneuploid
strains created by meiosis of triploid budding yeasts displayed a bias to
loss of extra chromosomes, which could potentially lead to euploidy
[45]. Disomic budding yeasts aswell as yeasts with complex aneuploidy
maintain their abnormal karyotype for several generations [14,16], al-
though increased chromosomal instability has been reported in these
cells [5,6,13]. In populations of model human trisomic cells loss of the
entire extra chromosome does not occur frequently even after exten-
sive passaging (Silvia Stingele and Z.S., unpublished observations).
These observations indicate that there is no active cellular mechanism
that enables restoration of normal gene copy numbers. Rather the in-
creased genomic instability of aneuploid cells sporadically produces eu-
ploid cells that can potentially outgrow the aneuploid population.
4. Dosage compensation by altering the mRNA levels in aneuploids
Down-regulation or up-regulation of gene transcription might be
another effective mechanism to compensate the gene dosage changes
in aneuploids, as this maintains the stoichiometry and preserves the en-
ergy required for transcription, translation and eventual degradation of
the extra proteins. However, most of the transcriptional analyses of
model aneuploid cells in budding and ﬁssion yeasts, plants, mice and
human cells have indicated that mRNA levels scale with gene copy
number [12,14,15,18,46–48]. The only exception identiﬁed so far is Dro-
sophila, where a signiﬁcant buffering of the mRNA abundance of genes
encoded on aneuploid chromosomal regions was observed [49,50]. In
particular, the expression of genes frommonosomic regions was stron-
ger than the expected 50% of the diploid, typically around 60–80%. The
dosage compensation was more efﬁcient for large, non-ubiquitously,
highly expressed genes and appeared to be limited, as larger monoso-
mic regions were compensated less efﬁciently than smaller mono-
somies [49]. The mRNA levels from trisomic chromosome 4 were also
signiﬁcantly compensated in Drosophila cells. The dosage compensa-
tion of chromosome 4 is mediated by the protein Painting of Fourth
(POF) that binds to nascent RNA speciﬁcally on this chromosome and
increases transcriptional output [51,52]. Intriguingly, it has now been
demonstrated, based on its feminizing properties and patterns of gene
expression, that Drosophila chromosome4 is in fact an ancient sex chro-
mosome that has reverted to an autosome [53]. Viewed in this light, the
chromosome-speciﬁc silencing of chromosome 4 would appear to be
the vestige of a sex-determining silencingmechanism. In contrast, anal-
ysis of the chromosomal deletions on chromosome2 L in Drosophila re-
vealed only a gene-speciﬁc dosage compensation that depended on
gene-speciﬁc regulatory networks [44]. Thus, Drosophila has evolved
and maintained besides the usual dosage compensation of sex chromo-
somes another chromosome-speciﬁc dosage compensationmechanism
for modulating gene transcription of chromosome 4.
Additionally, feedback control that buffers the mRNA levels of am-
pliﬁed or deleted chromosomal regions has been suggested in nat-
urally occurring yeast strains [23] as well as in lager brewing yeast [22].
The mechanisms involved in this phenomenon remain enigmatic, but
interestingly the analyzed ampliﬁed genes were located mostly in
subtelomeric regions, which might affect their expression [22].In the ﬁssion yeast Schizosaccharomyces pombe, mRNA abundance
increases according to the chromosome copy number changes [47]. Re-
cent genome-wide genetic analysis determined genes encoding sub-
units of the Ccr4–Not complex to be essential for the survival of
progenies of triploid mitosis in ﬁssion yeasts, and this genetic require-
ment has also been conﬁrmed in aneuploid budding yeast [54]. Ccr4–
Not is a conserved and essential multi-subunit complex (Ccr4, Caf1,
Caf40, Caf130, Not1-5 in budding yeast) involved in negative and posi-
tive regulation of transcription initiation, mRNA elongation, RNA degra-
dation as well as deadenylation of the poly(A)-tail. Its primary function
is likely the regulation of mRNA turn-over upon stress conditions and
defects in Ccr4–Not result in accumulation of excessive mRNA
(reviewed in [55]). In addition, the subunit Not4 displays ubiquitin li-
gase activity and the Ccr4–Not complex interacts with the nascent-
associated polypeptide complex and is implicated in the degradation
of arrested translation products [56,57]. Given the wide-ranging role
of the Ccr4–Not complex in regulation of gene expression it is difﬁcult
to pinpoint which function is essential in aneuploids. In future, exact
quantiﬁcation of mRNA and protein abundance in aneuploid yeast
with and without the Ccr4–Not complex will allow discrimination of
whether the genetic requirement reﬂects the mRNA-linked functions
of Ccr4–Not, its role in ubiquitin-mediated degradation or other so far
unknown molecular activities.
Taken together, the expression of aneuploid somatic chromosomes
can be partially compensated by modulating mRNA expression, but the
extent and the molecular mechanisms remain unclear. Future work will
show whether the autosomal dosage compensation in Drosophila is an
exception among eukaryotes. Additionally, a feedback mechanism due
to the inherent regulatory characteristics of transcriptional networks
might compensate the copy number changes for some genes. A detailed
analysis of the gene expression changes within transcriptional networks
will reveal to what degree feedback control contributes to dosage com-
pensation in aneuploid cells. Finally, dosage compensation at themRNA
level wasmostly observed in segmental aneuploidies and the efﬁciency
was inversely correlated with the size of the supernumerary regions.
This suggests that there is a threshold of gene copy number changes be-
yond which the mechanisms operating on the mRNA level fail to “bal-
ance out” the aneuploidy.
5. Changes of protein levels in aneuploid cells
Whilemost studies into the effects of aneuploidy on gene expression
analyzed the changes in mRNA levels, comparable analyses of protein
abundance were until recently missing. However, developments in
mass spectrometry and data analysis now enable quantiﬁcation of
whole proteomes, which has greatly facilitated examination of the pro-
teome changes in aneuploids. Such analyses have been carried out for
budding yeast [16,58], and human cell lines [18] carrying supernumer-
ary chromosomes. These studies have revealed that the correlation
between DNA copy number and protein level is strong in aneuploid
cells, with the majority of proteins encoded on extranumerary chromo-
somes being signiﬁcantly overexpressed relative to proteins encoded on
euploid chromosomes [58,16,18]. However, in certain cases a lower or
higher than expected abundance of proteins is observed. A striking
insight from these analyses is that the members of multi-subunit com-
plexes encoded on extra chromosomes are preferentially adjusted to-
wards diploid levels [58]. This is in line with previous observations that
the abundance of subunits from the same macromolecular complexes is
tightly co-regulated, and that deregulated expression of individual sub-
units leads to changes in expression levels of other subunits [59]. A very
recent report offers a plausible and attractive molecular mechanism for
these observations by showing that N-terminal acetylation-induced pro-
tein degradation [60] of protein complex members is suppressed upon
binding of the member to its ligands in the complex [61]. In our previous
work, we identiﬁed kinases as a second class of proteins subject to com-
pensation at the protein level [18]. In contrast to the ﬁndings mentioned
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determined in the proteome analysis of complex aneuploid yeast, al-
though it should be noted that therewas a trend towards reduced protein
levels in four out of the ﬁve strains analyzed [16]. The reason for the dis-
crepancy between results obtained with disomies and with complex
aneuploids is currently not clear; we speculate that the different ap-
proaches used to generate the two sets of aneuploid cells may play a
role. While the disomes were generated under selection pressure for
the presence of a speciﬁc extra chromosome [58], the complex aneu-
ploids arose as the ﬁttest survivors resulting from themeiosis of triploid
and pentaploid progenitors [16]. Thus, it is possible that this latter
approach led to selection for karyotypes characterized by less severe stoi-
chiometric imbalances. In addition, the different strategies used to ana-
lyze the data in the two studies may have led to the differing results.
Taken together, however, the limited data on protein composition in
cells with whole chromosomal aneuploidy suggest that while the levels
of most proteins scale with the gene dosage, at least some protein classes
are expressed at signiﬁcantly lower levels.
While the above described studies reported on the effects of super-
numerary chromosomes, thework of Springer et al. analyzed the effects
of single gene deletions on gene expression [62]. In approximately 80%
of the deletions tested, the protein levels scaledwith DNA copy number
(i.e. a 50% reduction in levels of the gene translated into a 50% drop in
protein levels). Less than 5% of analyzed factorswere entirely compensat-
ed; i.e. they showed no changes in protein levels in comparison to wild
type diploids. These factors were not enriched for subunits of protein
complexes [62]. However, the experimental set up of the study did not
enable determination of whether the remaining members of the protein
complexes (i.e. the non-deleted ones) were compensated to any extent.
In contrast, examination of more general correlations between gene
copy number and protein levels in aneuploid cancer cells revealed only
a small effect of gene copy number on protein levels [63]. Strikingly, the
protein abundance remained virtually unaffected by changes in gene
copy number for the members of several protein complexes such as the
26S proteasome, ribosome, and spliceosome. This compensation was
not due to changes in the mRNA levels of the genes in question and
thus, can be attributed to compensation taking place at the protein level
[63].
The compensation of the levels of certain proteins in aneuploid cells
carrying supernumerary chromosomes on one hand, and the observed
detrimental effects of abnormal stoichiometries on the other, might
imply the existence of active mechanisms that sense and respond to
abundance changes of certain classes of protein; however, no suchmech-
anisms have been identiﬁed so far. Alternatively, the observed phenome-
non of dosage compensation in aneuploid cells could essentially be an
unregulated response resulting from the physiological changes triggered
by aneuploidy. Moreover, the difference between the near lack of com-
pensation at the protein level in “monosomy” (as in deletions) and partial
compensation in disomy or trisomy might suggest that the involved
mechanisms rely primarily on protein degradation. Regardless of wheth-
er the process is active or not, it is reasonable to assume that it must in-
volve modulation of the machinery which governs cellular protein
homeostasis or “proteostasis”. In the following sections we will discuss
what is currently known regarding how aneuploidy affects the activity
of the proteostasis network and howdefects in proteostasismay underlie
the dosage compensation and perhaps other phenotypes of aneuploid
cells.
6. Maintenance of proteostasis in aneuploid cells
Proteostasis has been deﬁned as “the state of dynamic equilibrium in
whichprotein synthesis and folding is balancedwith degradation,while
allowing for the conformational ﬂexibility necessary for function, thus
leading to a ‘healthy proteome’” [64]. The proteostasismachinery encom-
passes all factors that participate in and contribute to protein synthesis,
folding, trafﬁcking, disaggregation and degradation. An important facetof this concept is that an imbalanced or impaired proteostasis network
will lead to proteotoxic stress, cellular dysfunction and disease [65].
There is now emerging evidence that in aneuploid cells the activity of the
proteostasis network is either compromised or becomes overwhelmed
due to the extra load of proteins. Although the precise mechanisms un-
derlying the apparent proteotoxic stress in aneuploid cells are still not
fully understood, recent data have provided ﬁrst glimpses into the conse-
quences of imbalanced gene expression for cellular proteostasis.
6.1. Aneuploidy impairs protein folding
Aneuploid yeast, mouse and human cells exhibit many of the hall-
marks of cells undergoing proteotoxic stress as manifested in enhanced
sensitivity to translation inhibitors and increased temperature [14],
elevated levels of autophagy and sensitivity to inhibitors of lysosomal
degradation [18,66], the presence of cytoplasmic protein inclusions
[18,67], and hypersensitivity to exogenous expression of toxic protein
aggregates [67]. This is dependent upon the active transcription of
genes from supernumerary chromosomes as transcriptionally silent
yeast artiﬁcial chromosomes (YACs) introduced into yeast failed to elic-
it the sameeffect [67]. The heat shock response and its induction remain
functional at least in aneuploid yeast [67], but aneuploidy by itself does
not induce the expression of molecular chaperones in most of the ana-
lyzed organisms [14,15,18], although a slightly increased level of several
heat shock proteins was observed in model aneuploid murine embry-
onic ﬁbroblasts [18,66]. The correct folding, stability and functionality of
most cellular proteins is dependent upon molecular chaperones that as-
sist and direct other proteins to adopt and maintain their proper struc-
ture [68]. An important characteristic of the relationship between
molecular chaperones and their clients is that chaperone capacity is close-
ly matched to the folding demands experienced by cells under a given
condition [69]. This is determined, in large part, through the inducible ac-
tivity of the master regulator of the cytosolic heat shock response, HSF-1
(Heat shock factor protein 1), which, in response to enhanced protein
folding demand, transcriptionally up-regulates multiple molecular chap-
erones [70]. We speculate that aneuploid cells experience low-level but
“creeping” chronic protein misfolding which fails to elicit HSF-1 induc-
tion. Indeed, cells do not copewell with such chronic misfolding [64], be-
cause as little as 0.1% of misfolded proteins are sufﬁcient to signiﬁcantly
decrease cellular proliferation capacity in budding yeast expressing a
metastable mutant allele of YFP [71].
What are the consequences of the protein folding stress experienced
by aneuploids? One important clue lies in the identity of the proteins
which are compensated in aneuploid cellswith extranumerary chromo-
somes [58]. Both protein complex members and kinases have very
speciﬁc and extensive requirements for the protein folding machinery
in order to adopt and maintain their correct conformations and to
bind their ligands. Remarkably, both classes of proteins have critical re-
quirements for the Hsp90 chaperonemachinery [72,73]. While the role
of Hsp90 is well recognized in the case of protein kinases [73], its impor-
tance for protein complex assembly is only emerging [72]. Based on this
knowledgewehypothesize that a defect in protein foldingmight underlie
the observed deviation of protein abundance from expected levels in
aneuploid cells with extranumerary chromosomes. In our model, the
synthesis, folding and degradation of proteins encoded on supernumer-
ary chromosomes either creates exaggerated competition for limiting fac-
tors essential for the maintenance of proteostasis, or compromises the
protein folding capacity of the cell in a more indirect manner (Fig. 3).
This competition or impairment likely leads to low-level but chronic pro-
tein misfolding and, in turn, either to aggregation, or destabilization and
degradation of proteinswith high demands on the chaperonemachinery,
such as subunits of protein complexes, kinases and possibly others. The
protein folding deﬁciency likely impairs the expression of many cellular
proteins, but the relative changes might be most apparent for those pro-
teins that are encoded on the extra chromosomes and rely heavily on
chaperone function. Indeed, our own analysis has revealed that the
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Fig. 3. Proposedmodel of dosage compensation in aneuploid cells. In our proposedmodel
for dosage compensation at the protein level in aneuploid cells, the increased gene expres-
sion and protein production in these cells leads to competition for a limiting number of
proteostasis factors, here depicted as the molecular chaperones, Hsp70 and Hsp90. This
competition leads to chronic protein misfolding and subsequent degradation via the UPS
or autophagy. Those proteins subjected to misfolding are likely to have exaggerated or
speciﬁc requirements for the chaperone machinery, such as, for example kinases or the
subunits of macromolecular complexes.
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are also expressed at lower levels in aneuploid cell lines compared to dip-
loid controls [18]. In summary,we suggest that the apparent dosage com-
pensation of protein levels observed in budding yeast and human cells
carrying extranumerary chromosomes is a side-effect of the protein fold-
ing defect triggered by imbalanced gene expression.6.2. Protein degradation in aneuploid cells
From the hypothesis proposed above it follows that pathways in-
volved in protein degradation play an important role inmediating the ob-
served compensation of proteins from supernumerary chromosomes and
also potentially other key phenotypes of aneuploid cells. Indeed, since
protein synthesis and folding are intimately linked with degradation
within the proteostasis network, it is logical that deﬁciencies in protein
folding will affect the activity of pathways involved in protein degrada-
tion: the ubiquitin–proteasome system (UPS) and autophagy.In the UPS, client substrates targeted for degradation via the
multicatalytic 26S proteasome complex are marked by covalent attach-
ment of ubiquitin [74]. The rate of protein degradation by the UPS is
mediated by the balance between proteasome activity, free ubiquitin,
ubiquitin ligases, and deubiquitylating (DUB) enzymes [75]. The UBP6
gene encodes a DUB, which was proposed to reduce the proteasomal
degradation of its substrates; conversely, deletion of this gene leads
to elevated degradation of some proteasome substrates [76,77]. In-
terestingly, the homolog ofUBP6 is strongly downregulated in Drosoph-
ila aneuploids [78]. The exact function of this protein remains under
debate, as Ubp6 is also implicated in promoting proteasomal degrada-
tion of ubiquitinated substrates [79]. Nevertheless, deletion of the
UBP6 gene in aneuploid budding yeast leads to lower levels of proteins
that are encoded on supernumerary chromosomes, improves the prolif-
eration of these cells to levels comparable with haploid controls [58],
and dramatically reduces the levels of protein aggregates in such cells
[67]. This suggests that accumulation of the extra proteins encoded on
the added chromosome inhibits cell proliferation and that after increas-
ing proteasomal turnover these excess proteins are effectively degrad-
ed, thus allowing aneuploid cells to overcome their proliferative
disadvantage.
While these landmark ﬁndings highlight the detrimental effects of
excess levels of proteins from supernumerary chromosomes and sug-
gest a critical role for the UPS in aneuploid cells, important questions re-
main unanswered. Most pointedly, it remains unknownwhat the protein
inclusions in aneuploid cells are composed of, and whether they are
enriched for proteins encoded on supernumerary chromosomes. Also, it
is unclear what the role of the UPS is in disposing of excess proteins
from supernumerary chromosomes in general, and compensated pro-
teins, in particular. More broadly, it has yet to be determined how aneu-
ploidy affects total ﬂux through the UPS. The presence of cytoplasmic
protein inclusions in aneuploid cells may indicate an overwhelming or
impairment of proteasomal activity in aneuploid cells [18,67], and aneu-
ploid yeasts are consistently more sensitive to treatment with the pro-
teasome inhibitor, MG132 [14]. In contrast, aneuploid MEFs are slightly
more resistant than their diploid counterparts to inhibition of the pro-
teasome [66]. The reason for this observation is not yet understood
but it suggests that mammalian aneuploid cells do not rely as heavily
on proteasomal degradation as do their budding yeast counterparts,
possibly because of enhanced degradation through the autophagic
pathway (see below).
Our recent genome-wide analysis of the transcriptome and pro-
teome of human aneuploid cells revealed an enrichment of factors
involved in lysosomal degradation [18]. The lysosome is known to de-
grade proteins that are either delivered via autophagosomes or directly
transferred to the lysosome. Autophagy is highly active in human aneu-
ploid cells as demonstrated by the observations that the number of
autophagosomes approximately doubles and autophagic ﬂux is not di-
minished [18]. Similarly, model murine aneuploid cells exhibit higher
levels of autophagy and are more sensitive to autophagy-inhibiting
drugs than diploids [66]. Interestingly, yeast aneuploids were shown
to accumulate cytoplasmic protein aggregates, but no autophagy activa-
tion has been reported so far. One of themost consistently up-regulated
proteins identiﬁed in human aneuploids was SQSTM1/p62. Additional-
ly, p62-positive foci that colocalized with ubiquitin foci were increas-
ingly formed in the cytoplasm of human tri- and tetrasomic cell lines
[18]. p62 binds to ubiquitylated proteins and likely sequesters them in
aggregates or protein inclusions in the cytoplasm [80-82]. The aggregat-
ed proteins are preferentially degraded by autophagy [83] because
proteasomal degradation requires unfolding of the substrate to pass
through the pore of the proteasome [84]. Therefore, we speculate that
themisfolded proteins which accumulate in aneuploid cells are seques-
tered by p62 and targeted for degradation via autophagy [85]. Future
experiments should clarify what regulates the extent of protein aggre-
gation in aneuploid cells and how this aggregation is linkedwith the au-
tophagic machinery.
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documented, the cues and molecular mechanisms leading to induction
of autophagy by aneuploidy remain a mystery. Previously it has been
shown that aneuploid yeast and human cells exhibit increased glycoly-
sis and oxidative metabolism, which may suggest nutrient deprivation
[14,18]. Autophagy is activated in response to starvation and thus it is
possible that the lack of nutrients and energy triggers autophagy in an-
euploid cells. However, p62 usually decreases upon starvation, whereas
the opposite is observed in human aneuploid cells [18,85]. Alternatively,
the protein folding stress and protein misfolding experienced by aneu-
ploid cells may lead to increased autophagic activity. Understanding
the basis for the autophagy activation in aneuploid cellswill provide im-
portant insight into the effects of aneuploidy on proteostasis and cellu-
lar physiology. Moreover, research on model aneuploid cells might
contribute to our understanding of proteostasis and of the functional in-
teractions between the three main players — protein folding, UPS and
autophagy.
Other degradation machineries besides proteasomes and lysosomes
might contribute to the removal of extra proteins in aneuploid cells. In an-
euploid Drosophila, factors with peptidase and proteolytic activity were
found among the 100most up-regulated genes [78]. The identiﬁed prote-
ases are poorly characterized cytosolic proteases that are not linked to the
UPS or lysosomes. The induction of proteolysis was lower when the gene
dosage buffering on mRNA level was efﬁcient, suggesting that protein
degradation serves as a back-up system for the maintenance of protein
homeostasis [78]. Taken together, maintenance of protein homeostasis
via protein degradation appears important in all aneuploid eukaryotic
cells analyzed so far, although different pathways are engaged, and to
varying degrees.
7. Conclusion
Aneuploidy and its often detrimental consequences for eukaryotic
cells were ﬁrst recognized more than a century ago. However, only in
the last decade has aneuploidy per se become a focus of intense research
thanks to novel genome-wide quantitative approaches that have enabled
the analysis of the consequences of chromosomal imbalance. These anal-
yses have revealed that some of the most striking phenotypes triggered
by aneuploidy, such as slow proliferation, impaired proteostasis, altered
energy metabolism and others, appear to be common features of aneu-
ploid cells from yeast to man. In particular, the machinery involved in
themaintenance of proteostasis appears to be overwhelmed and possibly
compromised in aneuploid cells. Yet, recent results suggest that different
organisms use different strategies to deal with this impaired proteostasis.
InDrosophila, dosage compensation ofmRNA encoded on the aneuploid
chromosomes moderates the impact of chromosome copy number
changes. However, inmost organisms the burden of copy number chang-
es is shouldered by the proteostasis network, inwhich the protein folding
machinery as well as pathways of protein degradation – autophagy,
UPS and cytosolic proteases – are affected. Interestingly, the current
data suggest that speciﬁc pathways might be involved to differing
extents in each species. Future research should address howexactly aneu-
ploidy affects the activity of the proteostasis network and whether im-
paired proteostasis also underlies the other phenotypes of aneuploid
cells such as reduced proliferation, increased chromosomal instability
and altered metabolic requirements.
The majority of cancer cells are aneuploid and thus the observations
made in model aneuploid cells might be also important in human can-
cers. In support of this hypothesis, it is well-established that cancer cells
are “addicted to chaperones” andHSF1 plays a critical, multifaceted role
in tumorigenesis [86]. In particular, Hsp90has been shown to be an excel-
lent target for cancer therapy and there are currently asmany as 15 differ-
ent Hsp90 inhibitors in clinical development, although the mechanisms
underlying the increased sensitivity of cancer cells to these inhibitors re-
main debated [87]. Finally, heightened activity and an increasing reliance
on autophagy are hallmarks of many established tumors [88], as is adependence on proteasomal degradation [89]. Taken together with our
developing understanding of the effects of aneuploidy on proteostasis,
these observations support the intriguing possibilities that profound
changes in proteostasis are a prerequisite for the development of aneu-
ploid cells into cancers, and conversely, that the increaseddemandof can-
cer cells for chaperones and processes of protein degradation stems, at
least in part, from their frequently abnormal karyotypes. Understanding
the contribution of aneuploidy to the cancer phenotype as well as the
basis for the sensitivity of aneuploid cancers to drugs which target
proteostasis will help to improve the efﬁcacy of cancer therapies that
rely on this strategy.Acknowledgments
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